PRRTInfo.org - A Resource for Patients Considering PRRT Treatment.

PRRTinfo.org is a site for patients considering PRRT (Peptide Receptor Radionuclide Therapy) treatment in Germany written by patients for patients.   While much of this information can be used by patients seeking treatment at any PRRT Center worldwide, this site focus is on the treatment as provided by Dr. Richard Baum and his team at the Zentralklinik Bad Berka in Bad Berka, Germany. 

As of Jan 1, 2020. Dr. Baum has moved from Zentralklinik Bad Berka and now practices at  the THERANOSTICUM Frankfurt-Wiesbaden
at DKD Clinic. Please see the article below that details these changes.

PRRT has continued to evolve since this site was first launched in May of 2011. in 2017/18 Lu177 Dotatate was approved in Europe and

As of January 2020, Dr. Baum will be located at the THERANOSTICS CENTER FOR RADIOMOLECULAR PRECISION ONCOLOGY in Wiesbaden  (very close to Frankfurt/Main airport (20 minutes by car or commuter train)). Dr. Baum will have full access to complete diagnostic and treatment facilities. 
As of December 15, 2019, please use the following contact information:

Professor Dr. Richard P. Baum, MD, PhD
THERANOSTICUM Frankfurt-Wiesbaden
at DKD Clinic
Aukammallee 33
65191 Wiesbaden, Germany
https://www.praxis-nuklearmedizin.de/en/
To send an email This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Harshad R. Kulkarni, MD, will manage the care of those patients who will still need to be treated at ZBB due to special technical requirements (e.g. ALPHA-PRRT, intra-arterial PRRT

Videos from Patient Education Day on NETs from the SNMMI Annual Meeting

Philidelphia, June 2018 

Introduction to Theranostic from Zentralklink Bad Berka

1/26/18 - Advanced Accelerator Applications (AAA) Receives FDA Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine
AAA announced that the Federal Drug Administration (FDA) has approved the new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Click here to

Advanced Accelerator Applications (AAA) Receives European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine

AAA announced on September 29, 2017 that the European Commission (EC) has approved the marketing authorization of lutetium (177Lu) oxodotreotide* (Lutathera®) for “the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

The results from the first randomized control trial of PRRT were released today in Vienna, Austria showing increased progression free survival compared to high dose octreotide LAR.

PRRT while available in many parts of the world has not yet been approved for use pending prospective randomized clinical trails (RCT). Having a positive RCT for PRRT will greatly expand access and availability to PRRT around the world. Click here to download the full release.

At the 2nd Theranostics World Congress there was progress towards the treatment of metastatic prostate cancer using a Theranostics approach. At the 3rd Theranostics World Congress that progress continued from the bench and to the bedside.

This video is an overview of the treatment and management of metastatic prostate cancer using a Theranostic Approach.

  1. Ga68 Pet/CT Map
  2. IAEA Guidance on PRRNT for NETs